

**CURRICULUM VITAE****Name:** Rita Kramer, M.D.**Office:** Hematology/Oncology Division (843) 792-4271  
Medical University of South Carolina  
96 Jonathan Lucas Street - 903 CSB  
MSC 6350  
Charleston, SC 29425**EDUCATION:**

Transylvania University, Lexington, KY  
B.A. (Summa Cum Laude) Chemistry and Biology  
1980

University of Kentucky College of Medicine, Lexington, KY  
M.D. (with Distinction)  
1984

A.B. Chandler Medical Center, University of Kentucky  
Intern in Medicine  
1984 – 1985

A.B. Chandler Medical Center, University of Kentucky  
Resident in Medicine  
1985 – 1987

A.B. Chandler Medical Center, University of Kentucky  
Chief Resident in Medicine  
1987 – 1988

A.B. Chandler Medical Center, University of Kentucky  
Fellow, Hematology/Oncology  
1988 – 1991

A.B. Chandler Medical Center, University of Kentucky  
Postdoctoral Fellow, Microbiology and Immunology  
(supported by NIH F32 award)  
1991 – 1993

**PROFESSIONAL EXPERIENCE:**

Mini sabbatical to obtain experience in Intraperitoneal Chemotherapy  
University of California at San Diego  
Consulting Physician  
March, 1989

Biological Response Modifiers Program  
National Cancer Institute, National Institutes of Health  
Clinical Research Fellow  
October and November, 1989

Molecular Biology and Biotechnology Workshop  
Smith College, New England Biolabs  
Participant  
June, 1992

Molecular Biology in Clinical Oncology Workshop  
American Association for Cancer Research  
Participant  
July, 1992

Train the Trainer Workshop  
American Society of Clinical Oncology (Genetics Education Task Force)  
Invited Participant  
June, 1997

Kentucky Commission on Women  
Assisted in Developing Legislative Agenda for HealthCare for Kentucky Women  
Advisor  
June, 1997

**FACULTY APPOINTMENTS:**

Associate Professor of Medicine  
Division of Hematology/Oncology  
Medical University of South Carolina  
Charleston, South Carolina  
May, 2009 – Present

Associate Professor  
Baylor College of Medicine, Breast Center  
Houston, Texas  
07/2008 – 04/2009

Adjunct Associate Professor  
Baylor College of Medicine, Breast Center  
Houston, Texas  
03/2005 – 07/2008

Visiting Professor  
Hospital Universitario Doce de Octubre, Medical Oncology  
Madrid, Spain  
06/2005 – 10/2007

Distinguished Visiting Professor  
Universidad Complutense  
Madrid, Spain  
07/2007 – 09/2007

Associate Professor  
Baylor College of Medicine and the Methodist Hospital Breast Center  
Houston, Texas  
06/2002 – 02/2005

Associate Professor of Medicine  
Roswell Park Cancer Institute, Buffalo, NY and  
State University of New York at Buffalo, Buffalo, NY  
Department of Medicine  
06/2001 – 02/2002

Associate Professor of Medicine  
A.B. Chandler Medical Center, University of Kentucky  
Division of Hematology/Oncology  
09/1999 – 03/2001

Assistant Professor of Medicine  
A.B. Chandler Medical Center, University of Kentucky  
Division of Hematology/Oncology  
1993 – 1999

Clinical Scholar  
A.B. Chandler Medical Center, University of Kentucky  
1991 – 1993

**LICENSURE:**

South Carolina  
Texas  
Kentucky

**HOSPITAL APPOINTMENTS:**

Director, Hematology and Oncology Fellowship  
University of Kentucky  
Lexington, Kentucky  
1997 – 2001

Co-Director, Interdisciplinary Breast Fellowship Program  
Baylor College of Medicine  
Houston, Texas  
2004 – 2005 (This was the first Interdisciplinary Breast Fellowship Program at Baylor. I developed the program with Dr. Kent Osborne and we obtained the initial funding for the program from The Susan G. Komen Breast Cancer Foundation (Period: July 2004 – June 2006 Direct Costs/Current Year/total: \$35,000/year x 2 years))

**CLINICAL AND ADMINISTRATIVE ACTIVITY:**

1. Member Comprehensive Breast Care Center, University of Kentucky; 1994-2001.
2. Director, Berea Outreach Clinic, University of Kentucky; 1994-2001.
3. Member, College of Medicine Research Committee, University of Kentucky college of Medicine; 199-1999.
4. Co-Director, Hereditary Cancer Program, University of Kentucky; 1996-2001.
5. Director Fellowship Program, Division of Hematology/Oncology A.B. Chandler medical Center University of Kentucky; 1997-2001.
6. Member; Medical School Admissions Committee, University of Kentucky, Lexington, KY; 1998-1999.
7. Member, Appointment, Promotion and Tenure Committee, Department of Internal Medicine, University of Kentucky, Lexington, KY; 1998-2001.
8. Member, Surgical Pathology Committee, University of Kentucky, Lexington, KY; 1998-2001.
9. Member, Cancer Center Product Line Committee, Markey Cancer Center, University of Kentucky, Lexington, KY; 1998-2001.
10. Chair, Chemotherapy Infusion Room Renovation Task Force, Markey Cancer Center, University of Kentucky, Lexington, KY; 1999-2000.

11. Member, Comprehensive Breast Care Center Roswell Park Cancer Institute, Buffalo, New York; 2001-2002.
12. Reviewer, Institutional Review Board, Roswell Park Cancer Institute; 2001-2002.
13. Member, Data Safety Monitoring Committee (DSMB), MD Anderson Community Clinical Oncology Program, Houston, Texas; 2001-2005.
14. Chair, Adult Working Group, Protocol Review and Scientific Monitoring Committee, The Cancer Center, Houston, Texas; 2004-2005.

### **BOARD CERTIFICATION:**

- 1985 National Board of Medical Examiners
- 1988 Diplomate of American Board of Internal Medicine
- 1991 Diplomate of American Board of Internal Medicine  
Subspecialty of Medical Oncology
- 2002 Recertified, Medical Oncology

### **HONORS AND AWARDS:**

- 1988 Clinical Fellowship, American Cancer Society
- 1989 Clinical Fellowship, American Cancer Society
- 1991 National Research Service Award (F32), National Institutes of Health
- 1999 Fellow, American College of Physicians, American Society of Internal Medicine
- 2000 Senior Women in Medicine, Association of American Medical College Professional Development Seminar
- 2004 Who's Who in Medical Sciences Education
- 2007 Distinguished Visiting Professor Award, Complutense University, Medical Oncology Service, Doce de Octubre Hospital, Madrid Spain

### **RESEARCH PRESENTATIONS: NATIONAL and INTERNATIONAL:**

1. Immune Responses in Patients with Breast Cancer Treated with An Ani-Idiotypic Antibody that Mimics the Human Milk Fat Globule (HMFG) Antigen. Oral Paper, Cancer Vaccine Therapy, American Society of Clinical Oncology Meeting, May

- 1998.
2. Mechanisms of Tamoxifen Resistance, AstraZeneca Investigator's Meeting, Madrid, Spain, July 2003.
  3. Hormonal Therapy for Breast Carcinoma: Overcoming Resistance. 1<sup>st</sup> Breast Cancer Frontier Meeting, Tokyo, Japan, October 2003.
  4. Organizer and Co-moderator of mini-symposium titled "New Techniques in Breast Radiation", San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2003.
  5. Organizer and Co-Moderator of mini-symposium titled "Reaching and Treating Minorities and the Elderly", San Antonio Breast Cancer Symposium, San Antonio, Texas December 2003.
  6. Adjuvant Therapies in the Youngest and Oldest Patients, IV Santiago Internal Breast Cancer Symposium, Santiago, Chile, April 2004.
  7. State of the Art of Adjuvant Chemotherapy, IV Santiago International Breast Cancer Symposium, Santiago, Chile, April 2004.
  8. Organizer and Co-Moderator of mini-symposium titled "Breast Cancer Risk Assessment", San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2004.
  9. Organizer and Co-Moderator of mini-symposium titled "Breast Cancer in Younger Women", San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2004.
  10. Role of Translational Studies in Optimizing Palliative Chemotherapy. VI Madrid Breast Cancer Conference: Changes in the treatment of breast cancer, Madrid Spain June 1-3, 2005.
  11. Dissecting The Breast Pathology Report, Translator's Workshop, October 2006, Madrid Spain.
  12. Clinical Trials, Translator's Workshop, October 2006, Madrid Spain.
  13. Chest Wall Metastases: Biology & Therapy. VII Madrid Breast Cancer Conference: Changes in the treatment of breast cancer, Madrid Spain June 20-22, 2007.

**PUBLICATIONS:****Manuscripts**

1. Davey DD, **Munn RK**, Smith LW, Cibull ML: Angiotrophic Lymphoma. Arch Pathol Lab Med, 114:879-882, 1990.
2. Egan R, **Munn RK**: Catastrophic antiphospholipid antibody syndrome presenting with multiple thromboses and avascular necrosis. J of Rheumatology, 21(12): 2376-2379, 1994.
3. **Munn RK**, Pierce ST, Sloan D, Weeks JA: Malignant joint effusions secondary to solid tumor metastasis. J of Rheumatology 22(5):973-975, 1995.
4. Stuart PM, **Munn RK**, DeMoll E, Woodward JG: Characterization of Human T cell Enterocolitica Superantigen. Human Immunology 43(4):269-75, 1995.
5. Fleming, DR, Henslee-Downey, PJ, Romond EH, Harder EJ, Marciniak E, **Munn RK**, Messino MJ, Macdonald JS, Bishop M, Rayens MK, Thompson JS, Foon KA: Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: A comparative matched cohort study. Bone Marrow Transplantation 17(6):917-22, 1996.
6. Andrykowski MA, **Munn RK**, Studts JL: Interest in learning of personal genetic risk for cancer: A general population survey. Preventive Medicine 25(5):527-36, 1996.
7. **Munn R**, Henslee-Downey PJ, Romond EH, Marciniak E, Fleming DR, Messino MJ, Macdonald JS, Rayens MK, Harder EJ, Phillips G, Thompson JS: Treatment of leukemia with partially matched related bone marrow transplantation. Bone Marrow Transplantation 19:421-27, 1997.
8. Andrykowski MA, Lightner R, Studts JL, **Munn RK**: Hereditary cancer risk notification and testing: How interested is the general population? Journal of Clinical Oncology 15:2139-2148, 1997.
9. Sloan DA, Donnelly MB, Schwartz RW, Plymale MA, Strodel WE, Kenady DE, McGrath PC, Edwards MJ, Singletary SE, Evans DB, Souba WW, Bland KI and the **Breast Cancer Education Working Group**. The multidisciplinary structured clinical instruction module as a vehicle for cancer education. The American Journal of Surgery 173:220-225, 1997.
10. Klyachkin ML, Schwartz RW, Cibull M, **Munn RK**, Regine WF, Kenady DE, McGrath PC, Sloan DA: Thyroid lymphoma: Is there a role for surgery? The American Surgeon 64:234-238, 1998.
11. Sloan DA, Donnelly MB, Plymale MA, Schwartz RW, Edwards MJ, Singletary SE, Evans DB, Souba WW, Gadd M, Bland KI, and the **Breast Cancer Education Working**

- Group:** Improving residents' clinical skills with the structured clinical instruction module for breast cancer: Results of a multiinstitutional study. *Surgery* 122(2):324-333, 1998.
12. Carpenter JS, Andrykowski MA, Cordova M, Cunningham L, Studts J, McGrath P, Kenady D, Sloan D, **Munn R**: Hot flashes in postmenopausal women treated for breast cancer: Prevalence, severity, correlates, management, and relation to quality of life. *Cancer* 82:1682-1691, 1998.
  13. **Munn RK**, Kramer CA, Arnold SM: Spinal cord compression due to extramedullary hematopoiesis in beta-thalassemia intermedia. *International Journal of Radiation Oncology Biology Physics* 42:607-609, 1998.
  14. Fleming DR, Henslee-Downey PJ, Ciocci G, Romond EH, Marciniak E, **Munn RK**, Thompson JS. The use of partially HLA-mismatched donors for allogeneic transplantation in patients with mucopolysaccharidosis-I. *Pediatr Transplantation* 2:299-304, 1998.
  15. Phillips GL, Davey DD, Hale GA, Marshall KW, **Munn RK**, Nath R, Reece DE, VanZant G: Granulocyte-colony stimulating factor (G-CSF)-primed, delayed marrow harvests as a source of hematopoietic stem cell progenitor cells for allogeneic transplantation. *Leukemia and Lymphoma* 35(3-4):303-309, 1999.
  16. Carpenter JS, Andrykowski MA, Freedman RR, **Munn R**: Feasibility and psychometrics of an ambulatory hot flash monitoring device. *Menopause* 6(3):209-215, 1999.
  17. Howard DS, Phillips GL, Reece DE, Pomeroy C, **Munn RK**, Pittard M: Adenoviral infections in hematopoietic stem cell transplant recipients. *Clinical Infectious Diseases* 29:1494-1501, 1999.
  18. Arnold SA, Young AB, **Munn RK**, Patchell R, Nanayakkara N, Markesbery WR: Expression of p53, bcl-2 E-cadherin and matrix metalloproteinase-9 in paired primary tumors and brain metastasis. *Clinical Cancer Research* 5:4028-4033, 1999.
  19. Hale GA, Reece DE, **Munn RK**, Kniska AB, Phillips GL: Blood tacrolimus concentrations in bone marrow transplant patients undergoing plasmapheresis. *Bone Marrow Transplantation* 25:449-451, 2000.
  20. Reece DE, Foon KA, Bhattacharya-Chatterjee M, Hale GA, Howard DS, **Munn RK**, Nath R, Plummer BA, Teitelbaum A, Phillips GL: Use of the anti-idiotypic vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer. *Bone Marrow Transplant* 26(7):729-735, 2000.
  21. Phillips GL, Hale GA, Howard DS, Nath R, **Munn RK**, Marshall KW, Reece DE, Reed E, VanZant G: G-CSF primed autologous marrow harvest and Transplantation in Cytapheresis "Mobilization Failure" Patients: A Descriptive analysis; *Bone Marrow Transplantation*. *Hematology* 5:223-231, 2000.

22. Reece DE, Foon KA, Battacharya-Chatterjee M, Adkins D, Broun EF, Connaghan DG, Dipersio JF, Holland HK, Howard DS, Hale GA, Klingemann HG, **Munn RK**, Raptis A, Phillips GL. Interim analysis of the use of the anti-idiotypic breast cancer vaccine 11D10 (TriAb ) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. *Clinical Breast Cancer* 2(1):52-58, 2001.
23. Reece DE, Foon KA, Chatterjee MD, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DA, Hale GA, Klingemann HG, **Munn RK**, Raptis A, Phillips GL. Use of the Anti-Idiotypic Breast Cancer Vaccine 11D10 in Conjunction with Autologous Stem Cell Transplantation in Patients with Metastatic Breast Cancer. *Clinical Breast Cancer. Suppl* 4:S152-7, Feb 3 2003.
24. **Kramer RM**. Invited commentary on The New Generation of Targeted Therapies for Breast Cancer. *Oncology* 17(10):1355-1356, 2003.
25. **Kramer R**. 26<sup>th</sup> Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 3-6 December 2003: update on clinical research. *Breast Cancer Res* 6(2):84-87, 2004
26. **Kramer R**, Brown P. Should tamoxifen be used in Breast Cancer Prevention? *Drug Safety.* 27(13):979-89, August 2004.
27. **Kramer R**, Osborne CK. Comparison of Nolvadex 20 mg and placebo combination to Nolvadex 20 mg and ZD 1839 (Iressa™) 250 mg combination in patients with metastatic breast cancer and estrogen receptor (ER) and/or progesterone receptor (PR) positive tumors. *Signal.* 5(3):18-20, September 2004.
28. Thompson, JS, Pomeroy C, Kryscio RJ, Brown SA, Reece D, **Kramer R**, Howard DS, VanZant G, Humphries S, Phillips G. Use of T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients. *Biol Blood Marrow Transplant* 10(12):858-66, 2004.
29. Friedman LC, **Kramer RM**. Reproductive Issues for Women with BRCA Mutations. Monograph of the Journal of the National Cancer Institute. 34:83-6, 2005.
30. Tham YL, Sexton K, Weiss HL, Elledge RM, Friedman LC, **Kramer RM**. The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause. *J Support Oncol.* June:4(6):295-8, 2006.
31. Tham YL, Sexton K, **Kramer R**, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. *Cancer* 107(4):696-704, 2006.
32. Tham YL, Sexton K, Weiss, H, Elledge R, Friedman LC, **Kramer R**. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. *Am J Clin Oncol.* 30(2):126-32, 2007.

## Abstracts

1. Bryan C, **Munn RK**, John W, Macdonald JS, Marshall ME: Treatment of Hormone Refractory State D Prostate Carcinoma with CHIP (NSC #256927). Proc Am Soc Clin Oncol 8:148, 1989 (Abstract 579)
2. **Munn RK**, Bryan CS, Henslee-Downey PJ, Parr MD, Romond EH, Messino MJ, Doukas MA, Macdonald J: A randomized trial to determine the efficacy of 2-Mercaptoethane Sulfonate (MESNA) as prophylaxis against hemorrhagic cystitis in bone marrow transplantation (BMT). Exp. Hematology 18:701, 1990 (Abstract 575).
3. **Munn RK**, Stuart DM, Straley S, Woodward JG: Yersinia enterocolitica is a possible superantigen for human T cells. The FASEB J Vol 5, Num 4, A727, 1991 (Abstract 2074).
4. Stuart DM, Straley S, **Munn RK**, Woodward JG: T cell responses to yersinia superantigen. The FASEB Journal Vol 5, Num 5, A1362, 1991 (Abstract 5650).
5. John WJ, Cantrell J, Smith M, **Munn RK**, Neefe J: Treatment of advanced colorectal cancer with low-dose continuous infusion fluorouracil and interferon-alpha. Proc Am Soc Clin Oncol 10:148, 1991 (Abstract 457).
6. **Munn RK**, Brockman J, Woodward J: Cellular & Molecular Control of Major Histocompatibility Complex Antigen Expression. AACR 34: 502, 1993 (Abstract 3000).
7. **Munn RK**, Henslee-Downey PJ, Romond E, Bishop M, Harder E, Marciniak E, Thompson JS: Two to six year follow-up of partially matched related bone marrow transplants in pediatric patients with malignant and non-malignant diseases. Presented at Marrow Transplantation in Children: Current Results & Controversies. March, 1994.
8. **Munn RK**, Henslee-Downey PJ, Romond EH, Marciniak E, Thompson JS, Phillips G: Partially Matched Related Donor Marrow Transplantation (BMT) for Leukemia. American Society of Clinical Oncology Meeting, 1995 (presented).
9. Fleming DR, Henslee-Downey PJ, Harder EJ, Romond EH, Marciniak E, **Munn RK**, Messino MJ, MacDonald JS, Bishop M, Rayens MK, Thompson S, Foon KA: Allogeneic Bone Marrow Transplantation with Partially Matched Related Donors for Advanced Acute Lymphoblastic Leukemia in Children and Adults (presented, Bone Marrow Transplantation).
10. Sloan DA, Donnelly MB, Schwartz RW, Plymale MA, Kenady DE, McGrath PC, Edwards MJ, Singletary SE, Evans DB, Souba WW, Bland KI and the **Breast Cancer Education Working Group**. The multidisciplinary structured clinical instruction module as a vehicle for cancer education. Annual Meeting of the Association for Surgical Education, Lexington, KY, April 10-13, 1996.

11. **Munn RK**, Gagliardi A, Stepick-Biek P, King R, Collins D: Serum vascular endothelial growth factor levels in women with breast cancer. American Associate for Cancer Research, Abstract #1298, 1996 (presented).
12. **Munn RK** Gagliardi A, Stepick-Biek P, King R, Collins D: Estradiol (E2) and serum vascular endothelial growth factor (VEGF) levels in normal women and women with breast carcinoma. 10th International Congress of Endocrinology, 1996.
13. Sloan DA, Donnelly MB and the **Breast Cancer Education Working Group**. The efficacy of a structured breast cancer skills course for primary care givers. Annual Meeting of the Association for Cancer Education, Chicago, Illinois, October 19, 1996 (presented).
14. Klyachkin ML, Schwartz RW, Cibull M, **Munn RK**, Regine WF, Kenady DE, McGrath PC, Sloan DA: Thyroid lymphoma: Is there a role for surgery? Annual Meeting of the Southeastern Surgical Contress, Nashville, TN, February 2-6, 1997 (presented).
15. Sloan DA, Donnelly MB, Plymale MA, Schwartz RW, Edwards MJ, Singletary SE, Evans DB, Souba WW, Gadd M, Bland KI and the **Breast Cancer Education Working Group**. Improving residents' clinical skills with the structured clinical instruction module for breast cancer: Results of a multi-institutional study. Annual Meeting of the Society of University Surgeons, Tampa Florida, February 12-16, 1997 (presented).
16. **Munn RK**, Ludwig G, Collins D, Gagliardi A: Tamoxifen induces apoptosis in human microvascular endothelial cells. 88th Annual Meeting of the American Association for Cancer Research, 1997 (presented).
17. Gagliardi A, Ludwig G, **Munn RK**, Collins DC: Tamoxifen inhibits endothelial cell migration and in vitro angiogenesis. 88th Annual Meeting of the American Association for Cancer Research, 1997 (presented).
18. Ludwig G, Gagliardi A, **Munn RK**, Collins DC: Effects of somatostatin analogues and tamoxifen on angiogenesis in vivo and endothelial cells in vitro. 88th Annual Meeting of the American Association for Cancer Research, 1997 (presented).
19. Studts JL, **Munn RK**, Gallion HH, Andrykowski MA: A psychoeducational group intervention for persons interested in BRCA1 testing: Preliminary results. Society of Behavioral Medicine, April 16-19, 1997, San Francisco, CA (presented).
20. **Munn RK**, Gagliardi A, Collins D: Tamoxifen inhibits growth and migration of non-transformed human microvascular endothelial cells. 50th Annual Symposium on Fundamental Cancer Research: Molecular Determinants of Cancer Metastasis, October 28-31, 1997, Houston, TX (presented).
21. **Munn RK**, Hutchins L, Garrison J, Sen G, Chakraborty M, Baral R, Romond E, Bhattacharya-Chatterjee M, Foon KA: Immune responses in patients with breast cancer treated with an anti-idiotypic antibody that mimics the human milk fat globule

- (HMFG) antigen. 34<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, May 16-19, 1998, Los Angeles, CA (presented).
22. Howard DS, Phillips GL, Reece DE, **Munn RK**, Pomeroy C, Flett M: Adenovirus infections in hematopoietic stem cell transplant recipients. Marrow Transplantation in Children: Current Results and Controversies--Meeting #4, June 25-27, 1998, Palm Beach FL (presented).
23. Carpenter JS, **Munn RK**, Andrykowski MA, and The Breast Working Group: Characteristics of hot flashes in postmenopausal breast cancer survivors: correlation between objective ambulatory skin conductance monitoring and subjective patient report. 21<sup>st</sup> Annual San Antonio Breast Cancer Symposium, December 12-15, 1998, San Antonio, TX (presented). Breast Cancer Research and Treatment 50(3):#453, 1998.
24. **Kramer R**. Role of translational studies in optimizing palliative chemotherapy. VI Madrid Breast Cancer Conference: Changes in the treatment of Breast Cancer. June 1-3, 2005. Abstract published in Breast Cancer Research 2005, 7(Suppl 1):S28.
25. Tham YL, Sexton K, **Kramer R**, Hilsenbeck S, Elledge R. Breast cancer phenotype associated with a propensity for central nervous system (CNS) metastasis. 28<sup>th</sup> Annual San Antonio Breast Cancer Symposium, December 8-11, 2005, San Antonio, TX. Breast Cancer Research and Treatment 94(suppl 1):#3020, 2005.
26. Tham YL, Sexton K, **Kramer R**, Weiss H, Grollman J, Minnix J, Friedman LC. The adherence of practice guidelines in the assessment of bone health in women with chemotherapy induced amenorrhea 28<sup>th</sup> Annual San Antonio Breast Cancer Symposium, December 8-11, 2005, San Antonio, TX. Breast Cancer Research and Treatment 94(suppl 1):#6070, 2005.
27. Wu M-F, Hilsenbeck SG, Tham Y-L, **Kramer RM**, Elledge RM, Chang JC, Friedman LC. The efficacy of sertraline for controlling menopausal symptoms in women with breast cancer. 30<sup>th</sup> Annual San Antonio Breast Cancer Symposium, December 13-16, 2007, San Antonio, TX. Breast Cancer Research and Treatment 106(suppl 1):#6088, 2007.

#### Book Chapters

1. **Munn R**: Transfusion Reactions. IN: Internal Medicine On Call, S. Haist, J.B. Robbins, L.G. Gomella (Eds.). Appleton & Lange, Norwalk, CT, 1991.
2. Wood D, **Munn R**, Glenn J: Testicular Tumor with Metastasis. IN: Cancer Diagnosis and Treatment - a textbook organized by American College of Surgeons for J.B. Lippincott, May 1994.
3. **Munn R**: Associate Editor. Internal Medicine On Call, S. Haist, J.B. Robbins, L.G. Gomella (eds.). Appleton & Lange, Norwalk, CT, 2002.

4. Andrykowski MA, Carpenter JS, **Munn RK**: Psychosocial Sequelae of Cancer Diagnosis & Treatment. In: Psychosocial Interventions with Medical conditions: Principles & Techniques Schein LA, Bernard HS, Spitz, HI & Muskin PR (Eds.), (p 79-131). New York: Brunner-Routledge, 2003.
5. **Kramer R**, Osborne K.: Evaluation of Patients for Metastasis Prior to Primary Treatment. In: Diseases of the Breast, 3<sup>rd</sup> Edition, JR Harris, ME Lippman, M Morrow and CK Osborne (Eds.). Lippincott Williams & Wilkins, Philadelphia, PA, 2004.
6. **Kramer R**, Osborne K.: Evaluation of Patients After Primary Therapy. In: Diseases of the Breast, 3<sup>rd</sup> Edition, JR Harris, ME Lippman, M Morrow and CK Osborne (Eds.). Lippincott Williams & Wilkins, Philadelphia, PA, 2004.
7. Tham YL, **Kramer R**, Osborne K: Evaluation of Patients for Metastasis Prior to Primary Treatment. In: Diseases of the Breast, 4<sup>th</sup> Edition, JR Harris, ME Lippman, M Morrow and CK Osborne (Eds.). Lippincott Williams & Wilkins, in press.